KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed FCF Margin for 4 consecutive years, with 140.6% as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, FCF Margin fell 7759.0% year-over-year to 140.6%, compared with a TTM value of 155.19% through Dec 2023, down 9146.0%, and an annual FY2024 reading of 406517.02%, up 4490304.0% over the prior year.
  • FCF Margin was 140.6% for Q3 2023 at Ginkgo Bioworks Holdings, down from 108.07% in the prior quarter.
  • Across five years, FCF Margin topped out at 13347.8% in Q4 2020 and bottomed at 158.89% in Q1 2021.
  • Average FCF Margin over 4 years is 1021.28%, with a median of 111.49% recorded in 2023.
  • The sharpest move saw FCF Margin crashed -1346272bps in 2021, then skyrocketed 14495bps in 2022.
  • Year by year, FCF Margin stood at 13347.8% in 2020, then tumbled by -101bps to 114.92% in 2021, then dropped by -15bps to 132.45% in 2022, then fell by -6bps to 140.6% in 2023.
  • Business Quant data shows FCF Margin for DNA at 140.6% in Q3 2023, 108.07% in Q2 2023, and 136.34% in Q1 2023.